Viral Hepatitis

Viral Hepatitis

Principal Syndromes

Prevalence and Distribution

Specific Therapy

Specific Prevention*

Hepatitis A (acute)

Global, often epidemic

None

Immune globulin, vaccine

Hepatitis B (acute and chronic)

Global

Interferon, other antivirals, including nucleoside analogs (eg, entecavir) and nucleotide analogs (eg, tenofovir disoproxil fumarate)Interferon, other antivirals, including nucleoside analogs (eg, entecavir) and nucleotide analogs (eg, tenofovir disoproxil fumarate)

Screening for hepatitis B surface antigen

Vaccine, hepatitis B immune globulin (HBIG)Vaccine, hepatitis B immune globulin (HBIG)

Hepatitis C (acute and chronic)

Global

Interferon, ribavirin, direct-acting antivirals (eg, protease inhibitors, nucleotide analog inhibitors, nonstructural protein 5A [NS5A] inhibitors)Interferon, ribavirin, direct-acting antivirals (eg, protease inhibitors, nucleotide analog inhibitors, nonstructural protein 5A [NS5A] inhibitors)

Screening for hepatitis C

Hepatitis D (delta)

Endemic pockets in several countries

People who inject illicit drugs at relatively high risk

Can infect only in the presence of hepatitis B

Interferon

None

Hepatitis E

Outbreaks

Genotypes 1 and 2: Developing countries

Genotypes 3 and 4: Europe; transmitted by eating undercooked pork products

Severe during pregnancy

None

Vaccine (not available in United States)

* Nonspecific precautions (eg, avoidance of body fluids of infected patients, aseptic precautions, routine hygiene measures, and use of appropriate personal protective equipment) are also recommended.

* Nonspecific precautions (eg, avoidance of body fluids of infected patients, aseptic precautions, routine hygiene measures, and use of appropriate personal protective equipment) are also recommended.